Ken Griffin Terns Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$6.49 - $10.8 $425,095 - $707,400	65,500 Added 102.5%	129,400 $1.08 Million
Q2 2024 Aug 14, 2024	BUY	$4.54 - $8.2 $256,510 - $463,299	56,500 Added 763.51%	63,900 $435,000
Q1 2024 May 15, 2024	SELL	$4.86 - $8.19 $40,338 - $67,977	-8,300 Reduced 52.87%	7,400 $48,000
Q4 2023 Feb 14, 2024	SELL	$3.37 - $6.86 $12,469 - $25,382	-3,700 Reduced 19.07%	15,700 $101,000
Q3 2023 Nov 14, 2023	BUY	$4.7 - $8.55 $940 - $1,710	200 Added 1.04%	19,400 $97,000
Q2 2023 Aug 14, 2023	BUY	$7.35 - $13.29 $141,120 - $255,167	19,200 New	19,200 $168,000

163

78.4M

450K

423K

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $250M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.